ARTICLE | Clinical News
Midostaurin regulatory update
October 4, 2010 7:00 AM UTC
The EC granted Orphan Drug designation for Novartis' midostaurin to treat mastocytosis. The protein kinase C (PKC) inhibitor is in Phase II testing to treat aggressive systemic mastocytosis (ASM) and...